Address: 301 A-Leela Business Park,M.V. Road, Andheri
Tel: +91 22 5677 4242
Quintiles Transnational is a pharmaceutical services company offering clinical, commercial, consulting and capital services. The Quintiles network consists of more than 20,000 employees in 60 countries.
Quintiles manages clinical trials on behalf of pharmaceutical customers, and provides the following services:
Management of clinical trials, data, projects and providing laboratory services
Providing customers with sales force, product and brand solutions.
Providing data-driven recommendations to help customers achieve success.
Creating strategic partnerships through financing and operational solutions.
Quintiles India is located amidst a rapidly growing local pharmaceutical market. With five offices spread across the country, we help clients take advantage of a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and tertiary care and teaching hospitals available for trials.
Other advantages: Quintiles India has solid relationships with leading medical centers and experienced English-speaking investigators. All studies are conducted to FDA and ICH GCP standards. Urban India’s literate population provides fast, efficient access to broad population groups with common and special disease profiles, allowing for rapid patient recruitment and faster study start-ups.
Quintiles helped develop or commercialize all of 2009’s top 50 best selling drugs or compounds and nearly 90% of all breakthrough products released on the market between 1996 and 2008.
Key Services in India:
Access to patients
Central laboratory services
Clinical monitoring and site management
Data management offering a functional service provider (FSP) business model
ECG monitoring services
Access through Our India Team to Quintiles Worldwide:
Undeniably, the landscape for CROs has dramatically changed compared to when you started in the 1990s. The idea of…
There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule…